MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Oramed Pharmaceuticals Company Profile (NASDAQ:ORMP)

Consensus Ratings for Oramed Pharmaceuticals (NASDAQ:ORMP) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.60 (189.93% upside)

Analysts' Ratings History for Oramed Pharmaceuticals (NASDAQ:ORMP)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016FBR & Co.Boost Price TargetOutperform$15.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016AegisReiterated RatingBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016Rodman & RenshawReiterated RatingBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015HC WainwrightBoost Price TargetBuy$24.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/8/2015MLV & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.20)($0.20)($0.20)
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)
Dividend History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Oramed Pharmaceuticals (NASDAQ:ORMP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/12/2016Nadav KidronCEOBuy1,000$6.95$6,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2015Miriam KidronCTOSell50,000$8.90$445,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Michael BerelowitzDirectorSell700$9.44$6,608.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015Michael BerelowitzDirectorSell1,300$8.70$11,310.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Nadav KidronCEOBuy2,600$3.88$10,088.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014Miriam KidronCTOSell31,699$8.41$266,588.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Miriam KidronCTOSell23,000$8.40$193,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Miriam KidronCTOSell8,301$9.41$78,112.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014Regals Capital Management LpMajor ShareholderBuy2,252$4.44$9,998.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2014Michael BerelowitzDirectorSell9,434$10.50$99,057.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Regals Capital Management Lpmajor shareholderBuy75,000$10.62$796,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2014Regals Capital Management Lpmajor shareholderBuy51,292$15.61$800,668.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2013Regals Capital Management LpMajor ShareholderBuy6,630$7.40$49,062.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Oramed Pharmaceuticals (NASDAQ:ORMP)
DateHeadline
06/26/16 10:11 AMCovering the Bases on Oramed Pharmaceuticals Inc. (NASDAQ:ORMP): Where is the Stock Going? - Press Telegraph
06/22/16 05:36 PMOramed Pharma (ORMP) Receives Milestone Payment Related to HTIT License, Investment Agreement
06/21/16 05:14 PMOramed Announces $6.5 Million Milestone Payment from HTIT
06/21/16 10:05 AMOramed Pharma (ORMP) Receives Milestone Payment Related to HTIT License, Investment Agreement - StreetInsider.com
06/20/16 07:17 AMStrong Buy Calls Count For Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) At 3 - Investor Newswire
06/20/16 07:17 AMOramed Pharmaceuticals Inc. (ORMP) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 09:19 AMORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -
06/11/16 08:20 AM3 Biotechs That Just Announced Successful Phase 2 Trials -
06/09/16 07:15 AMOramed to Present at the American Diabetes Association 76th Scientific Sessions - [PR Newswire] - Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing a study performed in animals with its orally ingestible insulin capsule, ORMD-0801, will be presented in a poster at the ADA 76th Scientific Sessions on June 11-13, 2016 in New Orleans. The poster was also selected to be included in a moderated tour of select posters. The American Diabetes Association's Scientific Sessions offers researchers and health care professionals from around the world the unique opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care.
06/06/16 09:22 AMStock Review and Earnings Check on Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - HNN
06/03/16 08:34 AMShare Rating Focus on Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - HNN - Share Rating Focus on Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 1 on shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Covering analysts will ...and more »
06/02/16 08:41 AMBuy, Sell Or Hold Rating For Oramed Pharmaceuticals Inc. (ORMP)? - Share Trading News - Buy, Sell Or Hold Rating For Oramed Pharmaceuticals Inc. (ORMP)?Share Trading News12/01/2015 – Oramed Pharmaceuticals Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 25 price target on the stock. 10/01/2015 – Rodman & Renshaw began new coverage on Oramed Pharmaceuticals Inc. giving the ...Oramed Pharmaceuticals Inc. (ORMP) Updated Broker RatingsRisers & FallersOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Daily Sentiment Score Of 0Markets DailyOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Price Target and Stock Rating SynopsisThe PostHNNall 5 news articles »
05/24/16 09:36 PMHold Calls Count For Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) At 0 - RealistInvestor.com - Hold Calls Count For Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) At 0RealistInvestor.comBuy calls count on Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)'s stock stands at 0 while Sell recommendations is 0. Hold recommendation is 0. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has a total of 4 Strong Buy recommendations and 0 Strong ...and more »
05/23/16 09:32 PMWeekly Biotech Report Part II, Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) - Market Exclusive - Market ExclusiveWeekly Biotech Report Part II, Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)Market ExclusiveThe two companies were Marinus Pharmaceuticals Inc (NASDAQ:MRNS), with its fragile X phase II proof of concept, and Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), which was set to report data from its phase IIb clinical trial in its lead candidate, ...After Last Week What Do Analysts Think Of Oramed Pharmaceuticals Inc. (ORMP)Share Trading Newsall 6 news articles »
05/23/16 04:14 PMORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure -
05/22/16 07:04 PMAfter Last Week What Do Analysts Think Of Oramed Pharmaceuticals Inc. (ORMP) - Share Trading News - After Last Week What Do Analysts Think Of Oramed Pharmaceuticals Inc. (ORMP)Share Trading News12/03/2013 – Capital Ideas Research began new coverage on Oramed Pharmaceuticals Inc. giving the company a “buy” rating. The share price of Oramed Pharmaceuticals Inc. (ORMP) was up +4.48% during the last trading session, with a day high of 8.62.
05/20/16 10:50 AMOramed Pharmaceuticals Inc. (ORMP) Updated Broker Price Targets - Share Trading News - Oramed Pharmaceuticals Inc. (ORMP) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Oramed Pharmaceuticals Inc. (ORMP). The latest reports which are currently in issue on Friday 20th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...
05/19/16 09:01 PMOramed Pharmaceuticals,(NASDAQ:ORMP) &Bristol-Myers Squibb Co(NYSE:BMY) Services Trader's Watch List - Wall Street 24 - Oramed Pharmaceuticals,(NASDAQ:ORMP) &Bristol-Myers Squibb Co(NYSE:BMY) Services Trader's Watch ListWall Street 24On Wednesday, Shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)lost-7.97% to $8.31. The share price is trading in a range of $8.07 – $10.51. The stock exchanged hands with 3.10 Million shares contrast to its average daily volume of 145,107shares ...and more »
05/19/16 10:32 AMActive Runners in Thrust- NXP Semiconductors (NASDAQ:NXPI), Oramed Pharmaceuticals (NASDAQ:ORMP), Hormel ... - Seneca Globe - Active Runners in Thrust- NXP Semiconductors (NASDAQ:NXPI), Oramed Pharmaceuticals (NASDAQ:ORMP), Hormel ...Seneca GlobeOramed Pharmaceuticals Inc. (NASDAQ:ORMP) keeps its position active in street, shares closed at $8.31 with crashes down of -7.97%. Oramed Pharmaceuticals Inc. (ORMP) released its positive top-line results from its Phase IIb study, deinked to evaluate ...and more »
05/19/16 10:32 AMActive Runners Buzz: Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), Seagate Technology PLC (NASDAQ:STX) - NYSE Journal (press release) - NYSE Journal (press release)Active Runners Buzz: Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), Seagate Technology PLC (NASDAQ:STX)NYSE Journal (press release)Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) belongs to Healthcare sector and Biotechnology industry. ORMP stock opened its last trade at $10.31 and after floating in a range of $8.07 to $10.51, settled at $8.31. ORMP stock lost -7.97% in total of its ...Stocks Swings: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), Lombard Medical, Inc. (NASDAQ:EVAR), Hasbro Inc ...Benchmark Monitorall 26 news articles »
05/18/16 09:27 PMStocks in the Spotlight: Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), CEL-SCI Corporation (NYSEMKT:CVM ... - The Point Review - The Point ReviewStocks in the Spotlight: Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), CEL-SCI Corporation (NYSEMKT:CVM ...The Point ReviewShares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) flew 0.55% to $9.08 at 12:11 PM EDT. The stock attained the volume of 2.59 Million shares recently versus average trading volume of 145,107 shares. If we take a look on its volatility, 20.18 percent ...and more »
05/18/16 09:27 PMOramed Pharmaceuticals, Inc. (ORMP) Drug News Sparks Profit-Taking in the Options Pits - Schaeffers Research (blog) - Channel News AsiaOramed Pharmaceuticals, Inc. (ORMP) Drug News Sparks Profit-Taking in the Options PitsSchaeffers Research (blog)Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) stock popped more than 16% out of the gate, and briefly traded above recent resistance at the round-number $10 level, following highly anticipated news on the company's oral insulin drug, ORMD-0801.Oramed Pharma (ORMP) Announces ORMD-0801 Phase IIb Met Primary Objective in T2DStreetInsider.comOramed Pharmaceuticals Details Positive Top-Line Results from Phase IIb Oral Insulin Study (NASDAQ:ORMP)Sonoran Weekly ReviewOramed's oral insulin capsule successful in mid-stage study in type 2 diabetics; shares up 17% premarketSeeking Alphaall 9 news articles »
05/18/16 02:00 PMORMP: Oramed Announces Positive Top-Line Data from Phase IIb ORMD-0801 Study -
05/18/16 09:56 AMORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events -
05/18/16 08:23 AMOramed's Phase IIb Oral Insulin Study Meets Primary Safety And Efficacy Endpoints -
05/18/16 06:30 AMOramed says oral insulin succeeds in midstage type 2 diabetes trial -
05/18/16 06:25 AMOramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study - [PR Newswire] - Oramed Pharmaceuticals Inc. (ORMP), today announced positive top-line results from its Phase IIb study, designed to evaluate the safety and efficacy of its oral insulin capsule (ORMD-0801) in patients with type 2 diabetes. "This demonstration of safe and effective oral insulin delivery represents a transformative event in the treatment of type 2 diabetes," said Nadav Kidron, Oramed CEO. "These are very impressive results that confirm the efficacy of orally delivered intestinally absorbed insulin," said Dr. Michael Berelowitz, Head of Oramed's Scientific Advisory Board.
05/17/16 07:21 PMNotable Eye-Catching Stocks: Alphabet Inc (NASDAQ:GOOG), Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) - NYSE Journal (press release) - Notable Eye-Catching Stocks: Alphabet Inc (NASDAQ:GOOG), Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)NYSE Journal (press release)On Monday, shares of Alphabet Inc (NASDAQ:GOOG), added 0.80% and Closed at $716.49 in the last trading session. The last trading range of the stock ranges between $705.65 and $718.48. Picture an 18-wheel truck barreling down the highway with ...and more »
05/16/16 08:03 PMOramed Pharmaceuticals, Inc. (ORMP) Option Buyers, Analysts Anxious for Data - Schaeffers Research (blog) - Schaeffers Research (blog)Oramed Pharmaceuticals, Inc. (ORMP) Option Buyers, Analysts Anxious for DataSchaeffers Research (blog)The shares of drugmaker Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) are at it again, thanks to escalating optimism ahead of key drug data. On Friday, ORMP surged after Rodman & Renshaw said the data could be "transformative" for ORMP; today, the ...Oramed Pharmaceuticals Inc. (ORMP) Updated Analyst CoverageRisers & FallersBroker Outlook For The Week Ahead Oramed Pharmaceuticals Inc. (ORMP) - Share Trading.NewsShare Trading NewsOramed Pharmaceuticals, Inc.'s Stock Is Buy After Forming Multiple Top PatternWall Street Hints and NewsSonoran Weekly Review -Vanguard Tribune -Is storiesall 12 news articles »
05/16/16 08:49 AMOramed to Present at Oppenheimer Annual Israeli Conference - [PR Newswire] - Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenheimer Annual Israeli Conference, taking place on May 22, 2016 in Tel Aviv. Nadav Kidron, CEO of Oramed, will present a corporate overview at the conference. Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
05/13/16 10:08 PMMid-day Healthcare Stocks to Track: Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) - The Point Review - The Point ReviewMid-day Healthcare Stocks to Track: Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)The Point ReviewShare of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) traded on -20.42 percent above secure line at 2:57PM EDT in order to take the company's stock at the price of $6.85. At the time of writing the stock exchanged hands 771,202 shares versus average ...Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)'s Company Shares Decreased 0.91% After High VolatilityFranklin IndependentOramed Pharmaceuticals Inc. (ORMP) Files Form 4 Insider Buying : Nadav Kidron Buys 1000 SharesMarket DigestIs Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Stock a Buy after Nadav Kidron's Insider Trading?The PostAnalyst Ratingsall 5 news articles »
05/12/16 01:45 PMORMP: Today’s Decline In Share Price Not Justified -
05/11/16 06:27 PMOramed Patent Being Granted in China for Oral Administration of Proteins - [at noodls] - JERUSALEM, May 11, 2016 /PRNewswire/ - Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that an official Notification of Granting ...
05/07/16 12:16 AMAverage Analyst Rating for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - B.O.D.Y Confidential - Average Analyst Rating for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
05/05/16 01:29 AMOramed's Pending Oral Insulin Would Trounce Efforts Of Global Diabetes Titans - Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), far ahead of its bigger brethren, just got closer to fulfilling this dream. Early last month, Oramed finished its 180-patient Phase IIb clinical trial with ORMD-0801, an oral insulin pill intended to mimic natural ...
05/03/16 12:27 AMOramed Pharmaceuticals Inc. (ORMP) Broker Price Targets For The Coming Week - Share Trading News - Oramed Pharmaceuticals Inc. (ORMP) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Oramed Pharmaceuticals Inc. (ORMP). The latest reports which are currently in issue on Monday 2nd of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...Oramed Pharmaceuticals Incorporated (NASDAQ:ORMP) Shorts Decreased by 1.26% After Short CoveringFranklin Independentall 5 news articles »
04/29/16 09:38 PMOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Share Rating Recap - B.O.D.Y Confidential - Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Share Rating RecapB.O.D.Y ConfidentialShares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly ...
04/28/16 06:27 PMOramed to Present at PIONEERS 2016, Presented by Joseph Gunnar - [at noodls] - JERUSALEM, April 28, 2016 /PRNewswire/ - Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, ...
04/27/16 09:59 PMOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Analyst Rating Review - The Post - Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Analyst Rating ReviewThe PostCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 4 analysts that have provided ratings for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). 4 have rated the ...and more »
04/27/16 09:59 PMBroker Roundup For Oramed Pharmaceuticals Inc. (ORMP) - Share Trading News - Broker Roundup For Oramed Pharmaceuticals Inc. (ORMP)Share Trading News12/03/2013 – Capital Ideas Research began new coverage on Oramed Pharmaceuticals Inc. giving the company a “buy” rating. The share price of Oramed Pharmaceuticals Inc. (ORMP) was down -0.69% during the last trading session, with a day high of 8.75.Oramed Pharmaceuticals Incorporated (NASDAQ:ORMP) Short Interest Decreased By 0.69%Franklin Independentall 2 news articles »
04/27/16 05:30 AMOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Share Rating Recap - The Post - Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Share Rating RecapThe PostShares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly ...and more »
04/26/16 08:24 PMOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Wall Street Rating in Focus - News Tribune - Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Wall Street Rating in FocusNews TribuneZacks.com, founded by Len Zacks, a Mathematics Ph.D. from M.I.T. who discovered that earnings estimate revisions are the most powerful force impacting stock prices, track 4 equity research firms that cover shares of Oramed Pharmaceuticals Inc.and more »
04/26/16 05:12 AMOramed Pharmaceuticals Inc. (ORMP) Latest Broker Coverage - Risers & Fallers - Oramed Pharmaceuticals Inc. (ORMP) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Oramed Pharmaceuticals Inc. (ORMP). According to the latest broker reports outstanding on Monday 25th of April, 0 analysts have a rating of “strong buy”, 0 analysts ...
04/23/16 02:30 AMBroker Outlook For Oramed Pharmaceuticals Inc. (ORMP) - Share Trading News - Broker Outlook For Oramed Pharmaceuticals Inc. (ORMP)Share Trading NewsThe most recently updated broker views and price targets issued for Oramed Pharmaceuticals Inc. (ORMP) are below. 12/29/2015 – Broker: FBR Capital Markets Rating: outperform New Target: 15 reiteration. 12/01/2015 – Broker: H.C. Wainwright Rating: buy ...Oramed Pharmaceuticals Incorporated (NASDAQ:ORMP) Shorts Decreased by 0.69% After Short CoveringB.O.D.Y Confidentialall 2 news articles »
04/23/16 02:30 AMUpgrades And Downgrades For Oramed Pharmaceuticals Inc. (ORMP) - Risers & Fallers - Upgrades And Downgrades For Oramed Pharmaceuticals Inc. (ORMP)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Oramed Pharmaceuticals Inc. (ORMP). The latest broker reports which are currently outstanding on Friday 22nd of April state 0 analysts have a rating of “strong buy”, 0 ...
04/19/16 11:34 PMOramed Pharmaceuticals Inc. (NASDAQ:ORMP): Where are Shares Headed? - News Tribune - Oramed Pharmaceuticals Inc. (NASDAQ:ORMP): Where are Shares Headed?News TribuneResearch analysts covering Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares have provided price target projections on the popular stock. They project that the shares are expected to reach $20.75 within the upcoming year. This consensus number ...and more »
04/19/16 11:34 PMTracking Earnings for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - RiversideGazette.com - Tracking Earnings for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)RiversideGazette.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP) has a current consensus EPS estimate for the quarter of $-0.19 based on Street analyst predictions. The company is scheduled to next report earnings information on or around 2016-07-06 for the period ending ...and more »
04/13/16 10:50 AMOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Analyst Recommendation Outlook - Clinton Financial - Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Analyst Recommendation OutlookClinton FinancialCovering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings estimates. There are 4 analysts providing ratings for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). 4 have given the stock a “Strong Buy”, ...and more »
04/12/16 11:03 PMOramed Pharmaceuticals Inc. (ORMP) Latest Broker Views - Risers & Fallers - News TribuneOramed Pharmaceuticals Inc. (ORMP) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Oramed Pharmaceuticals Inc. (ORMP). According to the latest broker reports outstanding on Tuesday 12th of April, 1 analyst has a rating of “strong buy”, 3 analysts ...Q2 2016 EPS Estimates for Oramed Pharmaceuticals, Inc. Boosted by Analyst (ORMP)The Vista VoiceOramed Pharma (ORMP) Receives Patent Term Adjustment from USPTO for '456 PatentStreetInsider.comOramed Pharmaceuticals Inc. (NASDAQ:ORMP): Quick Look at EarningsNews TribunePR Newswire (press release)all 5 news articles »
04/12/16 07:15 AMOramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent - [PR Newswire] - Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Patent and Trademark Office (PTO) has issued a Patent Term Adjustment (PTA) extending the patent term by 18 months for its patent No. 9,259,456, titled, "Methods and Compositions for Oral Administration of Proteins". Oramed had previously announced receiving an allowance on the patent. The PTA increases the patent term from the standard 20 years from the date of its earliest non-provisional application to 21 years and 6 months, extending the term through March 2, 2028.
About Oramed Pharmaceuticals

Oramed Pharmaceuticals logoOramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed's flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed's delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company's products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ORMP
  • CUSIP:
Key Metrics:
  • Previous Close: $8.14
  • 50 Day Moving Average: $8.43
  • 200 Day Moving Average: $7.77
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $106.76M
  • Current Quarter EPS Consensus Estimate: $-0.67 EPS
Additional Links:
Oramed Pharmaceuticals (NASDAQ:ORMP) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha